A 5-YEAR, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER STUDY ASSESSING THE EFFICACY, SAFETY, AND TOLERABILITY OF INTRA-ARTICULAR REGIMENS OF LNA043 VERSUS PLACEBO IN PATIENTS WITH SYMPTOMATIC KNEE OSTEOARTHRITIS (ONWARDS)
- Registry ID
- CLNA043A12202
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Study type
- INTERVENTIONAL
- Sponsor
- NOVARTIS PHARMACEUTICALS CANADA INC
- Start date
- 2022-05-27
- Last update
- 2021-05-07
Conditions
- OSTEOARTHRITIS OF THE KNEE
Related clinical trials
- MASTER PROTOCOL: A MASTER PROTOCOL FOR PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE WEEKLY ELORALINTIDE IN ADULT PARTICIPANTS WITH OSTEOARTHRITIS KNEE PAIN, AND OBESITY OR OVERWEIGHT (ENLIGHTEN-4)
- EFFICACY AND SAFETY OF NNC0487-0111 S.C. ONCE-WEEKLY IN PARTICIPANTS WITH OVERWEIGHT OR OBESITY, AND KNEE OSTEOARTHRITIS (AMAZE 6)
- EFFICACY AND SAFETY OF NNC0487-0111 S.C. ONCE-WEEKLY IN PARTICIPANTS WITH OVERWEIGHT OR OBESITY, AND KNEE OSTEOARTHRITIS (AMAZE 5)
- A PHASE 3 STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON ONCE DAILY
IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT AND OSTEOARTHRITIS OF THE KNEE: A
MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-ARM, PLACEBO-CONTROLLED TRIAL
(ATTAIN-OA PAIN)
- SINGLE DOSE PARALLEL COMPARATIVE BIOAVAILABILITY STUDY OF TRIAMCINOLONE
HEXACETONIDE FOLLOWING INTRA-ARTICULAR ADMINISTRATION OF A SINGLE DOSE INJECTION
OF TRIAMCINOLONE HEXACETONIDE (20 MG/ML) OR OF THE COMBINATION OF
TRIAMCINOLONE HEXACETONIDE (18 MG/4 ML) AND CROSS-LINKED HYALURONIC ACID
VISCOSUPPLEMENT IN MALE AND FEMALE PATIENTS WITH OSTEOARTHRITIS OF THE KNEE
- RECOMBINANT HUMAN GROWTH HORMONE (RHGH) FOR KNEE OSTEOARTHRITIS (KORR): A PILOT, RANDOMIZED PLACEBO-CONTROLLED TRIAL
View on source registry